FDA actions in brief
Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.
Sodium phosphate monobasic monohydrate/sodium phosphate dibasic anhydrous tablets (OsmoPrep, Salix) were approved by FDA for cleansing of the colon prior to colonoscopy in patients aged 18 years or older.
FDA approved omeprazole/sodium bicarbonate (Zegerid, Santarus), an immediate-release proton pump inhibitor (PPI), for the short-term treatment of active duodenal ulcers and erosive esophagitis diagnosed by endoscopy, the short-term treatment of active benign gastric ulcers, the maintenance of healing of erosive esophagitis, and for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD).
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More
